Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/14/2008

s -- (129,527)

Construction deposits (2,206,145) --

Contractor deposits 101,801 412,802

Addition to construction in progress (9,722,463) (12,961,091)

Proceeds from sale of equipment 61,152 --

Purchase of equipment and automobiles (360,192) (1,158,813)

Net cash used in investing (9,542,428) (18,525,646)

CASH FLOW FROM FINANCING ACTIVITIES:

Loan from (repayment to) related

parties 7,400,000 (843,115)

Payments on long term debt, related

party (1,065,000) --

Proceeds from share subscription in

subsidiary -- 18,000,130

Proceeds from joint venture investor

in Dongfeng 2,828 -

Payment to minority interest

shareholder (5,070,091) (6,676,102)

Net cash provided by (used

in) financing activities 1,267,737 10,480,913

EFFECTOF EXCHANGE RATE CHANGES ON CASH 3,053,932 1,272,215

INCREASE (DECREASE) IN CASH (6,340,515) 3,085,516

CASH, beginning of period 54,081,848 55,214,540

CASH, end of period $ 47,741,333 58,300,056

Supplemental disclosures of cash flow

information

Cash pain during the year for:

Interest (net of amount capitalized) $ 132,662 --

Income taxes $ 1,822,619 1,370,002

Note 1.

On December 20, 2007, the Company's subsidiary, Tianshi International

Holdings Group Ltd. (''Tianshi Holdings''),
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
2. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Yongye Biotechnology International Retains CCG Investor Relations
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
10. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
11. New Book on the Business of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... in Pharmaceutical Thin Film,Technology -, WARREN, N.J., ... specializing in quick dissolving thin film pharmaceutical products,today ... No. 7,425,292 from the,United States Patent and Trademark ... to issue on September 16, 2008, relates,to the ...
... Calif., Sept. 11 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... fourth quarter and year-end financial results on September,16, 2008., ... discuss its financial results.,Details for the fiscal year-end call ... 16, 2008 -- Time: 10:30 a.m. ET, 9:30 ...
... Deliver Yield Benefits and Value to Farmers, LONDON, ... a significant growth opportunity in continuing to create more ... and,breeding, leading to more than doubling the company,s 2007,s ... biotechnology, will,tell investors. Padgette will deliver his remarks as ...
Cached Biology Technology:MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 3Monsanto Sees Growing Opportunity for Biotech Traits Globally 4
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2The microbes make the sake brewery 2
... studied interactions between the loggerhead turtle ( Caretta caretta ) ... water surface, mass beachings, and the effects of climate change ... marine species without causing economic losses for fishermen, the scientists ... carried out by night and in areas more than 35 ...
... EAST LANSING, Mich. A team of Michigan State ... created have uncovered the inner workings of a ... develop new medicines or understand how enzymes repair DNA. ... bacterial enzyme that is important in metabolism. Enzymes in ...
... Copenhagen summit to draft a legally binding agreement on the ... that we will see further rapid changes in the global ... the planet,s most vulnerable species at this time of unprecedented ... on 26 February 2010 in the Journal of Experimental ...
Cached Biology News:How can accidental captures of loggerhead turtles be reduced? 2MSU scientists unlock key enzyme using newly created 'cool' method 2Tackling the challenges of survival in a changing world 2Tackling the challenges of survival in a changing world 3